Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer

NCT ID: NCT00290693

Last Updated: 2017-12-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-07-31
• Study Completion Date: 2010-06-30

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving capecitabine together with docetaxel works in treating patients with recurrent or progressive metastatic pancreatic cancer.

Detailed Description

OBJECTIVES:

Primary

• Determine the overall (complete and partial) response rate in patients with recurrent or progressive metastatic pancreatic cancer treated with capecitabine and docetaxel.

Secondary

• Determine the overall and progression-free survival of patients treated with the chemotherapy combination.
• Determine the duration of response (complete or partial) among patients who attain a response.
• Determine the frequency of patients having > 50% fall of CA19-9 from an initial level of > 100 U/mL in association with treatment with this regimen.
• Evaluate the toxicity associated with the administration of the combination in these patients.

OUTLINE: This is a multicenter, open-label, nonrandomized study.

Patients receive oral capecitabine twice daily on days 1-14 and docetaxel IV over 1 hour on days 1 and 8. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for up to 1 year.

PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study.

Conditions

Pancreatic Cancer

Keywords

recurrent pancreatic cancer; adenocarcinoma of the pancreas; stage IV pancreatic cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CapTere (Capecitabine + Docetaxel)

Capecitabine + Docetaxel (Taxotere)

Group Type: EXPERIMENTAL

Capecitabine

Intervention Type: DRUG

Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle

Docetaxel

Intervention Type: DRUG

30 mg/m2, IV, days 1 and 8 every 3 weeks

Interventions

Capecitabine

Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle

Intervention Type: DRUG

Docetaxel

30 mg/m2, IV, days 1 and 8 every 3 weeks

Intervention Type: DRUG

Other Intervention Names

Xeloda; Taxotere

Eligibility Criteria

Inclusion Criteria

1. Participants or their authorized legally acceptable representative must consent to be in the study and must have signed and dated an approved consent form which conforms to federal and institutional guidelines.

2. Patients must be 18 years or older.

3. Participants must have recurrence or progression of histologically or cytologically documented pancreatic adenocarcinoma. Re-documentation of tumor histology or cytology prior to protocol therapy is not required if documented tumor was confirmed prior to initial therapy.

4. Patients must have metastatic disease.

5. Patients with metastatic disease to the brain if they have received radiation therapy or are stable, and are not receiving steroids or anticonvulsants.

6. Participants must have received one prior gemcitabine based chemotherapy regimen (with or without radiation therapy). Participants must be 3 weeks or more beyond completion of prior chemotherapy (30 days beyond any experimental agent) and show recovery from toxicity to within the eligibility parameters of this protocol.

7. Radiation for palliation and of the primary tumor must have been completed at least four weeks prior to initiation of protocol therapy.

8. Patients must have measurable tumor by Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse et al, 2000). Measurable disease includes any lesion ≥ 1 cm by spiral CT or ≥ 2 cm by non-spiral CT in longest diameter which can be repetitively assessed by radiographic measurement or any lesion ≥ 2 cm in longest diameter which can be repetitively assessed by physical examination. Positive bone scans, osteoblastic or osteolytic bone lesions, pleural effusions and positive bone marrow biopsies are not considered acceptable as either measurable or evaluable lesions.

9. Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0,1, or 2.

10. Females of reproductive potential must not plan on conceiving children during the treatment period and must agree to use an effective medically accepted form of contraception. Patients will agree to continue contraception for 60 days from the date of the last study drug administration.

11. Required initial laboratory data:

• Granulocytes ≥ 1,500/µl
• Platelets ≥ 100,000/µl
• Hg ≥ 8.0 g/dL
• Creatinine ≤ 2.0 mg/dL
• Creatine Clearance >30 ml/min as calculated with Cockroft-Gault equation
• Bilirubin ≤ Upper Limits of Normal (ULN)
• Pregnancy test for females with child-bearing potential: Negative within 7 days of starting protocol

12. Transaminases (SGOT and/or SGPT) may be up to 2.5 x institutional upper limit of normal (ULN) if alkaline phosphatase is ≤ ULN, or alkaline phosphatase may be up to 4 x ULN if transaminases are ≤ ULN.

Exclusion Criteria

1. Patient currently enrolled in another clinical trial.

2. Pregnant or breast feeding women. With the exception of post-menopausal or infertile women, a negative blood test for pregnancy is mandatory before entry on study. Fertile persons refusing to use contraceptives may not participate.

3. Participants may not have had capecitabine or docetaxel as part of prior therapy.

4. No concurrent clinically evident malignancy is allowed except inactive non-melanoma skin cancer, low grade low stage bladder carcinoma followed off therapy, treated in-situ cervical cancer or lobular neoplasia of the breast.

5. Participants with serious uncontrolled medical or psychiatric illness that would render chemotherapy unsafe are ineligible.

6. Pregnant or breast-feeding at the time of proposed study entry.

7. Clinical AIDS or known positive HIV serology.

8. Peripheral neuropathy > grade 1

9. Patients with a history of severe hypersensitivity reaction to drugs formulated with polysorbate 80 must be excluded.

10. Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil.

11. Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.

12. Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.

13. Major Surgery within 4 weeks of the start of study treatment, without complete recovery.

14. Unwillingness to participate or inability to comply with the protocol for the duration of the study.

15. Patients with impaired renal function (estimated creatinine clearance < 30 ml/min as calculated by the Cockroft-Gault Equation).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Miami

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Caio Max S. Rocha Lima, MD

Role: PRINCIPAL_INVESTIGATOR

University of Miami

Locations

Mayo Clinic - Jacksonville

Jacksonville, Florida, United States

University of Miami

Miami, Florida, United States

Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center

Miami Beach, Florida, United States

Countries

United States

References

Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM. A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol. 2014 Apr;73(4):839-45. doi: 10.1007/s00280-014-2414-z. Epub 2014 Feb 23.

Reference Type: RESULT

PMID: 24562589 (View on PubMed)

Other Identifiers

SCCC-2003099

Identifier Type: OTHER

Identifier Source: secondary_id

WIRB-20051007

Identifier Type: OTHER

Identifier Source: secondary_id

AVENTIS-14056

Identifier Type: OTHER

Identifier Source: secondary_id

20030652

Identifier Type: -

Identifier Source: org_study_id